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Abstract 
 
 
Thanks to the use of human mesenchymal stem cells (hMSCs), smart biomaterials and 
active biomolecules, Regenerative Medicine (RM) and Bone Tissue Engineering (BTE) 
can restore structure and function of injured tissues.  
Among the different sources of hMSCs, the oro-facial hMSCs have promising in vitro and 
in vivo regeneration potential; in particular, dental pulp and gingiva are valuable sources 
of autologous hMSCs.  
The aim of this PhD thesis is testing the in vitro and in vivo bone regeneration ability of 
hMSCs isolated from dental pulp and inflamed gingiva of periodontally-compromised 
teeth, up to now considered biological waste tissues and discarded during surgical 
procedures, on two commercial scaffolds, FISIOGRAFT Bone Granular® and 
Matriderm®, in order to develop a low-cost and painless strategy of autologous bone 
tissue regeneration in patients affected by bone resorption.  
This project is in line with the National Operational Program (PON) “Research and 
Innovation” (R&I) 2014-2020 and the National Strategy of Intelligent Specialization 
(SNSI), aiming to promote the research and the innovation of the country, with a 
particular interest on the Health Specialization Area.  
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Summary 
 
 
Periodontitis, affecting from 20 to 50 % of the global population, is probably one of the 
most common diseases of the human beings. It starts from a localized inflammation of 
gingiva, induced by the microorganisms of the dental plaque, and, if not properly treated, 
it progresses to periodontitis responsible for bone resorption and tooth loss. In these 
cases, the prosthetic rehabilitation is not possible and Guided Bone Regeneration (GBR) 
procedures have been widely used to regenerate the bone. The autologous bone graft 
is currently the “gold standard” of the GBR procedures to allow the placement of dental 
prosthesis; however, the surgical procedures, implicating additional surgical sites, lead 
to higher costs of interventions and risks of clinical complications. Tissue Engineering 
(TE) and Regenerative Medicine (RM) are doing many efforts to identify alternative 
treatments; and, among the hMSCs so far investigated, Dental Pulp Stem Cells (DPSCs) 
and Gingival Mesenchymal Stem Cells (GMSCs) demonstrated to have promising 
abilities of bone regeneration. 
As integrating part of the PON R&I 2014-2020 and in line with the goals of the SNSI, the 
purpose of this PhD thesis is evaluating the in vitro and in vivo bone regeneration 
potential of DPSCs and GMSCs isolated from periodontally-compromised teeth, up to 
now considered biological waste tissues, on two commercial scaffolds, FISIOGRAFT 
Bone Granular® and Matriderm®, in order to develop a low-cost and painless strategy 
of autologous bone tissue regeneration in patients with bone resorption. Integrating the 
know-how of the University of Palermo and the expertise of the partner companies, this 
thesis aims to reach a Technology Readiness Level (TRL)-4 of the research, which 
constitutes the technological validation in laboratory, starting from the TRL-2, 
corresponding to the formulation of a technological concept. 
DPSCs-the low cell yield and/or high rate of bacterial contamination of the dental pulp 
samples did not allow the isolation of DPSCs; for this reason, after one year of research 
this line was abandoned. 
GMSCs-they were successfully isolated from gingiva of 18 healthy (Control group) and 
20 periodontally-compromised teeth (Test group). After having confirmed the stem cell 
phenotype by doubling time assay, colony-forming unit assay, and the expression of 
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hMSC markers, the GMSCs both from Control and Test group were seeded on the 
FISIOGRAFT Bone Granular® and Matriderm® scaffolds to evaluate the in vitro and in  
vivo cell viability and bone differentiation ability. 
The results demonstrated that the GMSCs from inflamed gingiva of periodontally-
compromised teeth, supported by the Matriderm® scaffold, may regenerate the bone in 
patients affected by bone resorption. 
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CHAPTER 1 
 
Background, Rationale and Objectives 
 
 
 
1.1  Periodontal disease and bone resorption 
Periodontitis is a multifactorial inflammatory disease affecting the tissues 
supporting the teeth: the gingiva, which is the soft tissue surrounding the teeth, 
the bone and the periodontal ligament, consisting of collagen fibers linking the 
tooth to the alveolar bone 1–3. Periodontitis starts from a localized inflammation of 
the gingival tissue, named as gingivitis, which is induced by an imbalance on the 
microbial biofilm forming the dental plaque 4–6. If not properly treated, the gingivitis 
progresses to periodontitis linked to bone resorption and tooth loss 7,8. 
Affecting from 20 to 50 % of the global population, gingivitis and periodontitis are 
among the most common diseases of human beings, representing a serious 
problem for the global health. Even though it can affect children and adolescents, 
it particularly affects adults between 35 and 44 years old 9,10. 
In case of teeth damage or loss, teeth are usually replaced by dental implants to 
restore the chewing, speech and aesthetic functions 11,12; however, 
osteointegration, firstly described by Branemark in 1977 and defined as the 
correct structural and functional connection between bone and dental prosthesis, 
is possible only when a sufficient bone volume is available to place the dental 
implants and establish a strong connection 13,14. It is widely known that patients 
affected by periodontitis suffer from bone resorption; in these patients, the 
restoring of the bone volume necessary to implant dental prosthesis is currently 
one of the main challenges of dentistry field 15–18 and alternative treatments are 
urgently needed 17,18. 
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1.2  Bone regeneration procedures  
Guided Bone Regeneration (GBR), based on the application of grafting materials 
and membranes, represents the most commonly protocol to regenerate the bone 
and allow the placement of dental implants 19–21. Noteworthy, thanks to the 
biocompatibility, osteoinductive and osteoconductive properties, the autologous 
bone graft is the “gold standard” of the GBR procedures, but its use is limited by 
the requirement of a second surgical site, resulting in increased possibility of 
clinical complications, morbidity, and higher costs of interventions. GBR 
procedures may also include the use allograft, xenograft or alloplastic materials, 
that can be used alone or in combination with autologous grafts 15,16,22. Usually, 
membranes are employed in GBR procedures; they protect the defect from 
invasion of soft tissue cells, allowing the bone progenitor cells to reach the 
membrane and regenerate the bone, and can be resorbable (e.g. polylactic acid 
(PLA), collagen, polyglactin) or not-resorbable (e.g. titanium-reinforced expanded 
polytetrafluoroethylene)20.  
In this scenario, easier and low-cost dental surgical procedures are needed to 
regenerate the alveolar bone in patients with bone resorption, as periodontal 
patients.  
 
1.3  Regenerative Medicine, Tissue Engineering and mesenchymal stem 
cells 
Regenerative Medicine (RM) and Tissue Engineering (TE), also indicated as 
TERM, provide new strategies to treat diseases and regenerate injured tissues 
and organs 23,24. 
TE was defined for the first time in 1993 by Langer and Vacanti as “an 
interdisciplinary field that applies the principles of engineering and life sciences 
toward the development of biological substitutes that restore, maintain, or 
improve tissue function or a whole organ”. It is able to regenerate tissues by 
relying on three main factors: stem cells, biomaterials and bioactive molecules. 
On the other side, RM has been defined as “the process of replacing or 
regenerating human cells, tissues or organs to restore or establish normal 
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function” by Mason & Dunnill in 2008 and takes advantage of stem cell ability to 
differentiate towards different cell types, being immunomodulatory and 
regenerate tissues in combination to nanomedicine, biomedicine and TE itself 25–
28. 
With their ability of clonogenicity, self-renewal and multi-differentiation ability, 
stem cells are the key to the regenerative process 29,30. The autologous hMSCs 
isolated from human adult tissues represent the ideal stem cell population to 
employ for autografts 30–34.  
Several hMSC sources have been identified as valuable sources for cellular 
therapy in TERM. Bone marrow (BM), umbilical cord blood and adipose tissue 
are currently among the most investigated tissues as source of hMSCs; however, 
the harvesting methods can be invasive and painful and, especially in case of 
BM, the number, the differentiation potential and the maximal life cycle of hMSCs 
decrease with the age of the subject 35,36. More recently, the efforts to identify 
other available sources of hMSCs, have led to characterize the oro-facial hMSCs, 
with a demonstrated potential of in vitro and in vivo tissue regeneration.  
 
1.4  Dental pulp stem cells  
Among the different stem cell “niches” found in the mouth, the pulp cavity of the 
tooth demonstrated to be a promising source of autologous hMSCs. The DPSCs 
were discovered by Gronthos et al in 2000, that found the presence of neural 
crest-derived stem cells in the dental pulp 37. In detail, the ectoderm-mesoderm 
interaction leads to the development of the tooth germ, where the neural crest 
cells differentiate in dental pulp, papilla and follicle.  
The hMSCs isolated from dental pulp of permanent teeth are called DPSCs; the 
hMSCs isolated from deciduous teeth are defined as SHEDs (Stem Cells from 
Human Exfoliated Deciduous Teeth) 38–40. 
DPSCs and SHEDs demonstrated to have clonogenic activity, multi-
differentiation potential and immunomodulation ability 39–41, and, if compared to 
BM-MSCs, they are easier to be harvested and demonstrated to have higher 
proliferation rate and osteo-differentiation ability 37,41–43. Noteworthy, it was 
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recently demonstrated that DPSCs, isolated from inflamed tissues, have 
enhanced stem cell properties and multi-lineage differentiation capability 44.  
These properties make them promising candidates for TERM applications 41,45,46.  
 
1.5  Gingival mesenchymal stem cells  
In the oral cavity, also gingiva 37,41,47–52, which is the soft tissue separating the 
periodontium from outer space, is considered a promising source of autologous 
hMSCs. The GMSCs, isolated for the first time in 2009 by Zhang et al. 50, 
represent a subpopulation of gingival fibroblasts, with well-demonstrated in vitro 
and in vivo abilities of self-renewal, multi-lineage differentiation, and 
immunomodulatory properties 53–55. 
Many biological characteristics make GMSCs ideal for TERM procedures: (i) they 
are easy to isolate and the patient can be submitted to the surgical biopsy without 
worrying about delayed healing; in addition, the vast majority of dissected gingival 
tissue is usually discarded during routine surgical procedures; (ii) in presence of 
specific conditions, they are able to differentiate towards mature osteoblasts, 
chondrocytes and adipocytes, expressing the relative cell lineage markers, 
phenotype and activity; (iii) they have a higher proliferation rate and multi-
differentiation ability than bone marrow mesenchymal stem cells (BM-MSCs); (iv) 
they display a stable phenotype, karyotype and normal telomerase activity in 
long-term cultures 54,56–61. 
Furthermore, as described for the DPSCs, the inflammatory microenvironment, 
characterizing the periodontally-affected periodontium, has demonstrated to 
positively affect the stem cell properties of GMSCs, showing higher proliferation 
rate, expression of hMSC markers, and ability of multi-lineage differentiation 44.  
 
1.6  Biomaterials 
Bone TERM is an interdisciplinary field that integrates principles of life sciences, 
medicine, chemistry and engineering, and investigates the relationship between 
structure and function of human tissues. Along with hMSCs, biomaterials are one 
of the main pillars of bone TERM and, as widely demonstrated, their composition, 
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structure and properties influence the cell attachment, growth and multi-
differentiation 62,63. 
The biomaterials can be synthetically produced or naturally derived. The 
advantage of using synthetic biomaterials is that they can be artificially modified 
(e.g. pore sizes, interconnection degree) as much as they need; however, their 
biocompatibility is lower than natural biomaterials. On the other hand, even if the 
natural biomaterials are weaker and softer than synthetic biomaterials, they are 
much more flexible and can adapt their shape to the required forms. Furthermore, 
the natural biomaterials usually contain specific natural domains that support and 
guide the cells in their development, thus improving the biological interactions 
with the tissue 39,62. 
All the biomaterials should have optimal mechanical properties and a functional 
micro-architecture with well-distributed and interconnected pores along the 
surface, to ensure the in vivo neovascularization 64,65. 
The integration between the expertise of the partner companies in smart 
biomaterials and the know-how of the University of Palermo on hMSCs 
contributed to carry on a research for the development of a quality biomedical 
experimental product with a TRL-4 and in line with the goals of one of the most 
currently investigated topics in the Health Specialization Area, the Regenerative 
and the Personalized Medicine.  
FISIOGRAFT Bone Granular®, from GHIMAS Spa (Bologna, Italy) and 
MatriDerm® from Medskin Solution, Dr. Otto Suwelack Skin and Health Care 
GmbH (Billerbeck, Germany) were used in this thesis project. 
 
1.7  FISIOGRAFT Bone Granular® 
Many types of scaffolds have been developed for bone TERM. The bone is a 
living tissue composed by an organic phase (i.e. collagen) and inorganic phase, 
mainly constituted by inorganic-based compounds as hydroxyapatite 66; for this 
reason, hydroxyapatite (HA) and calcium phosphate derivates, mimicking natural 
bone inorganic phase, have been mostly used for bone regenerative purposes 
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67,68. They can be used alone or in combination with additives such as polymers 
and bioactive molecules to repair bone defects 69. 
FISIOGRAFT Bone Granular® (GHIMAS Spa, Bologna, Italy) is a synthetic 
scaffold consisting of granules derived from a HA sponge of nanometric 
dimensions, with a morphological structure that mimics trabecular bone with very 
thin trabeculae, allowing the new bone to occupy a volume greater than that of 
xenografts. From the morphological point of view the synthetic sponge, based on 
nanometric hydroxyapatite, is homogeneous; it has a pore size from 500 to 1000 
μm and an interconnected porosity, which is optimal for cell proliferation 70. 
Noteworthy, a clinical study from Stacchi et al. 71 recently demonstrated that after 
6 months from FISIOGRAFT Bone Granular® implant in patients with maxillary 
sinus bone defect, the vital bone percentage was approximately 35 %, with a 
bone marrow space percentage of approximately 45 % and a residual graft 
percentage of roughly 21 %; in addition, after 12 months the implant survival rate 
was 96.4%, demonstrating its in vivo bone regeneration ability. 
 
1.8  MatriDerm® 
Type I collagen is the most represented organic polymer of bone matrix and plays 
an important role in the complex process of bone formation and remodeling. For 
these reasons, thanks to the excellent biocompatibility, biodegradability and weak 
antigenicity, and the ability of collagen fibrils to serve as a template for bone 
mineralization, collagen is a biomaterial widely used for tissue regeneration 72,73. 
MatriDerm® scaffold (Medskin Solution, Dr. Otto Suwelack Skin and Health Care 
GmbH, Billerbeck, Germany) is a three-dimensional matrix consisting of collagen 
type I (bovine collagen) and elastin (extracted from bovine ligamentum nuchae), 
possessing a porosity approximately of 100 µm and obtained by the Advanced 
CryoSafe™ Method, that preserves and refines the natural features and 
properties of biomaterials. Many studies recently demonstrated that MatriDerm® 
is able to support the crucial steps of tissue regeneration: cell migration and 
ingrowth, proliferation and neo-angiogenesis, essential for the regeneration 
process, successfully regenerating skin and cartilage tissues 74–76. 
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1.9  Bioactive molecules  
In bone regeneration techniques, besides to biomaterials with osteoinductive and 
osteoconductive properties, vascularization, growth factors, and mechanical 
environment are other crucial factors to reach the therapeutic goals 77,78. Growth 
factors and bioactive molecules are frequently used in association with 
biomaterials to improve the regeneration process; it was demonstrated that pure 
collagen materials don’t have enough osteoinductive activity to stimulate bone 
formation and many strategies, based on scaffold incorporation or hMSC 
treatment with bioactive molecules, have been developed 72,73,79. 
Biochanin A (5,7-dihydroxy-4’-methoxy-isoflavone), an isoflavone most 
commonly found in legumes as red clover (Trifolium pratense), is commercially 
available as a nutraceutical, a natural supplement used alone or in association to 
drugs to treat many diseases involving the bone health 80,81. Acting as a natural 
modulator of the α and β estrogen receptors, Biochanin A induces the 
transcriptional pathways physiologically activated by estrogens and inhibited 
during human pathological conditions as osteoporosis in post-menopausal 
women 82–86. In particular, Biochanin A showed to enhance the osteoblastic 
differentiation pathway and inhibit the osteoclastic differentiation pathway 87,88, 
contributing to maintain the bone health 80,81. 
In vitro and in vivo studies successfully showed that Biochanin A prevents the 
bone loss derived by ovariectomy, stimulating the osteoblastic activity and 
inhibiting the osteoclastic activity 87,88.  
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Aim of the PhD thesis 
The project of this PhD thesis is well-integrated in the National Operational Program 
(PON) “Research and Innovation” (R&I) 2014-2020 and the National Strategy of 
Intelligent Specialization (SNSI), with a particular interest on the Health 
Specialization Area for the application of the scientific knowledge and technology 
of biomedical and biotechnological fields; the project is based on the promotion 
and development of the Regenerative and Personalized Medicine to improve the 
life quality of patients affected by chronic-degenerative diseases as periodontitis.  
As part of this program, the aim of this thesis project is the assessment of the in 
vitro and in vivo bone regeneration ability of GMSCs and DPSCs isolated from 
periodontally-compromised teeth, up to now considered waste tissues, on two 
commercial nano-structured scaffolds, FISIOGRAFT Bone Granular® and 
Matriderm®, in order to develop a low-cost and painless strategy of autologous 
bone tissue regeneration for patients with bone resorption.  
The low cell yield and/or high bacterial contamination of dental pulp samples did 
not allow the DPSC isolation and evaluation of bone regeneration ability; instead, 
the GMSCs were successfully isolated from healthy (Control group) and inflamed 
gingiva (Test group). Stem cell phenotype was confirmed by doubling time assay, 
colony-forming unit assay, and expression of hMSC markers, while the in vitro 
and in vivo cell viability and bone differentiation ability of GMSCs from Control 
and Test group were evaluated on the FISIOGRAFT Bone Granular® and 
Matriderm® scaffolds, in presence or not of the isoflavone Biochanin A with pro-
osteoblastic activity.  
The hMSC know-how of the University of Palermo and the biomaterial expertise 
of the companies worked together to reach a biomedical experimental product 
characterized by a TRL-4, i.e. the technological validation in the laboratory, 
starting from the TRL-2, corresponding to the formulation of a technological 
concept. 
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CHAPTER 2 
 
 
Materials and Methods 
 
 
2.1 Ethics 
The protocol was approved by the Internal Ethical Committee of the University 
Hospital A.O.U.P “P. Giaccone” of Palermo (Internal registry: 5/2014). All 
subjects gave written informed consent in accordance with the Declaration of 
Helsinki. 
 
2.2 Patient identification and tissue extraction 
22 Healthy adult patients (ages 18-75) who needed extraction of wisdom teeth 
for orthodontic reasons (Control group) and 26 adult patients (ages 18-75) who 
needed extraction of molars suffering from periodontitis (mobility grade III) (Test 
group), without suspected or visible pregnancy in females, were recruited for the 
study.  
Before the extraction, each patient made a mouth rinse with 0,2% chlorhexidine 
for one minute (Meridol®, Gaba Vebas S.r.l., Rome, Italy) to decontaminate the 
oral cavity. Gingival tissues were resected from gingiva flaps during oral surgery 
procedures. 
 
2.3 Sample collection and establishment of primary cell cultures 
The samples were processed in the Laboratory of Regenerative Medicine 
(Department of Health Promotion, Mother and Child Care, Internal Medicine and 
Medical Specialties-ProMISE) headed by the Professor Carla Giordano. 
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After surgery, the pulpal and gingival tissues were collected in a 50-ml tube with 
cold, sterile Dulbecco's Phosphate Buffer Saline Solution w/o Calcium w/o 
Magnesium (DPBS w/o Ca2+/Mg2+) (Euroclone, Milan, Italy), containing 0,25 
mg/ml Levofloxacin, 0,40 mg/ml Gentamicin, 5 mg/ml Meropenem, and 0,25 
mg/ml Fluconazole, transported to the laboratory within 30 minutes and digested 
within 3 hours. 
The tissues were firstly mechanically digested using sterile scalpels and secondly 
enzymatically digested using a solution of Collagenase Type II (Gibco, Milan, 
Italy) 1 mg/ml for 2 hours at 37°C under agitation. After centrifugation of digests 
containing pulpal or gingival primary cells at 1200 rpm for 6’, the supernatant was 
removed, the pellet was re-suspended in fresh Dulbecco's Modified Eagle 
Medium/Nutrient Mixture F-12 (DMEM F-12) (Thermo Fisher Scientific, Milan, 
Italy), containing 10% of fetal bovine serum (FBS) (Euroclone, Milan, Italy), 100 
µg/ml Levofloxacin, 50 µg/ml Gentamicin, 50 µg/ml Meropenem, and 1,5 µg/ml 
Fluconazole, transferred in T25 culture flask (EuroClone, Milan, Italy), referred to 
as passage 0 (P0) and incubated at 37 °C and 5% CO2. The primary cells started 
to adhere to the flask in 4–5 days, and when they reached 80% of confluence 
(approximately 2 weeks), they were sub-cultured referred to as P1. By subculture 
P3, the antibiotic and antifungal cover was decreased and by subculture P4 it 
was completely abolished. Primary cells between P1 and P6 were used for the 
experiments in this study.  
hMSCs of dental pulp and gingiva from healthy patients are referred to as 
respectively H-DPSCs and H-GMSCs; hMSCs of dental pulp and gingiva from 
patients with periodontitis are referred to as respectively P-DPSCs and P-
GMSCs. 
 
2.4 Colony-Forming Unit Fibroblast Assay (CFU-F) 
H-GMSCs and P-GMSCs (P1) were seeded in 10-cm dishes at a density of 300 
cells/dish and cultured under conventional conditions, replacing old medium 
every 3 days. After 14 days, the cells were washed twice with DPBS, fixed in 4% 
paraformaldehyde and stained with 0.1% crystal violet. Only cellular groups 
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containing more than 50 cells were considered as colonies. Three sets of 
experiments for each sample were performed for calculations. 
 
2.5 Population doubling (DT) and cell proliferation curve 
The proliferation rate of H-GMSC and P-GMSCs was evaluated by trypan blue 
assay (Sigma-Aldrich, Milan, Italy) following the manufacturer’s instructions. H-
GMSCs and P-GMSCs (P2) were seeded at a density of 4 × 103 cells/cm2 in a 
24-well plate and grown up to 120 h. The cells were counted every 24 hours by 
observation under the optical microscope, after being stained with trypan blue. 
The DT was calculated in according to the literature data (Roth V. 2006 on the 
website http://www.doublingtime. com/compute.php). Three sets of experiments 
for each sample were performed for calculations. 
 
2.6 Flow cytometric immunophenotyping 
H-GMSCs and P-GMSCs (P5) were harvested and the cell pellet was re-
suspended in DPBS w/o Ca2+/Mg2+, at a concentration of 1x106cells/ml; then, 
5x105 cells/100 μl of cell suspension was used for every cytofluorimetric test. 
Briefly, the H-GMSCs and P-GMSCs were tested for expression of hematopoietic 
stem cell surface markers using FITC human anti-HLA-DR and anti-CD45 
monoclonal antibodies, and MSC surface markers using FITC human anti-CD29, 
CD90 and CD105, and PE human anti-CD73 (Table 1). Table 1 describes the 
conditions of antibody dilution, incubation and detection, following the 
manufacturer’s instructions. 
All reactions were then acquired using the FACS Calibur flow cytometer (Becton-
Dickinson, New Jersey, USA) and analyzed by the CellQuest Pro software. 
Specific IgG isotype antibodies were used as internal negative control. Unstained  
cells were used as negative control and BM-MSCs as a positive control (not 
shown).  
 
 
 
  16 
2.7 Isolation of total RNA and Real Time quantitative PCR (qRT-PCR) 
Isolation and purification of total RNA was performed using the RNeasy Mini Kit 
(Qiagen, California, USA), according to the manufacturer’s instructions. RNA 
quantity and quality were evaluated by NanoDrop 2000 (Thermo Fisher Scientific, 
Milan, Italy); 2μg of hMSC total RNA were reverse-transcribed to cDNA in a 
volume of 20μl with Oligo dT primers using the QuantiTect Reverse Transcription 
Kit (Qiagen, California, USA). To evaluate the stem cell gene profile and in vivo 
bone differentiation, quantitative PCR (qPCR) was performed using the 
QuantiNova SYBR Green PCR Kit and the RotorGene Q Instrument (Qiagen, 
California, USA). Briefly, the cDNA samples were mixed with the SYBR Green 
PCR master mix and specific pair of primers presented in Table 2. The qPCR 
conditions were as follows: denaturation at 95 °C for 3 min for 1 cycle, followed 
by 44 cycles of denaturation at 95 °C for 20 s, annealing at 60 °C for 30 s, and 
elongation at 72 °C for 60 s. Three technical replicates were performed for every 
sample. The specificity of the amplified products was determined by melting peak 
analysis. The relative expression of target genes was calculated using the ΔΔCt 
method according to the guidelines 89. β-actin was used as housekeeping gene 
to normalize the expression of target genes and BM-MSCs, used as a positive 
cell control, were used to compare gene expression. The results were presented 
in histograms using GraphPad Software and setting at 1 the gene expression of 
the positive cell control. hMSCs at P3 were used for the RT-qPCR analysis. 
 
2.8 Biomaterials 
The biomaterials used in the study were: FISIOGRAFT Bone Granular®, from 
GHIMAS Spa (Bologna, Italy) and constituted by sintered nanohydroxyapatite 
(NHA) microgranules, with a diameter between 250 and 500 μm, a pore size from 
500 to 1000 μm and obtained by crashing HA porous blocks; MatriDerm®, from 
Medskin Solution (Dr. Otto Suwelack Skin and Health Care GmbH, Billerbeck, 
Germany) and constituted by a three-dimensional matrix consisting of collagen 
(bovine collagen) and elastin (extracted from bovine ligamentum nuchae), with a 
porosity approximately of 100 µm and obtained by the Advanced CryoSafe™ 
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Method, able to preserve and refine the natural features and properties of 
biomaterials. 
 
2.9 Cell seeding 
Both types of biomaterials were provided by the companies in sterile conditions. 
They were incubated in culture media for 30 minutes at 37°C and 5% CO2, prior 
to cell seeding.  
For the viability test, 7400 cells/cm2 were seeded in 5 mg of the FISIOGRAFT 
Bone Granular® scaffold 90, in low-adhesion 96 well plate in order to inhibit the 
attachment of the cells to the bottom of the well and avoid false positive. After 
seeding, they were incubated at 37°C and 5% CO2 and the viability of H-GMSCs 
and P-GMSCs was evaluated after 24, 48, 72 hours by Water Soluble 
Tetrazolium Salt 1 (WST1).  
To perform the viability test on the MatriDerm® scaffold, 10000 cells/ cm2 were 
seeded in the scaffolds, using a 24 well plate. After cell seeding, the scaffolds 
were incubated at 37°C and 5% CO2 for 5 minutes without culture medium to 
promote the cell attachment; then, 1 ml of complete fresh medium was added to 
each scaffold and kept at 37°C and 5% CO2. After 24, 48, 72 hours 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay was 
performed to evaluate the viability of the cells. 
 
2.10 WST1 viability assay 
WST1 viability assay was performed to evaluate the viability of H-GMSCs and P-
GMSCs (P3) seeded on the FISIOGRAFT Bone Granular®. H-GMSCs and P-
GMSCs without scaffolds were used as controls.  
Briefly, after 3 hours of incubation with 2-(4-iodophenyl)-3-(4-nitrophenyl)-5-(2,4-
disulfophenyl)-2H-tetrazolium monosodium salt at 37°C and 5% CO2, the 
absorbance of the supernatant was read at 450 nm, using a microplate reader. 
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2.11 MTT viability assay 
MTT viability assay was performed to evaluate the viability of H-GMSCs and P-
GMSCs (P3) seeded on the MatriDerm® scaffold. H-GMSCs and P-GMSCs 
without scaffolds were used as controls.  
Briefly, after 4 hours of incubation with 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide salt at 37°C and 5% CO2, the absorbance of the 
supernatant was read at 570 nm, using a microplate reader. 
 
2.12 Live/Dead assay 
Live/Dead assay was performed to evaluate the survival of H-GMSCs and P-
GMSCs (P5) seeded on the MatriDerm® scaffold. Briefly, a dye mix of Ethidium 
Bromide (100 μg/ml) and Acridine Orange (100 μg/ml) in DPBS was used for the 
staining. At 24, 48 and 72 hours the scaffolds were washed twice with DPBS (100 
μl), every wash was run for 5 minutes by slight agitation. 
Live/Dead dye mix (30 μl) was added to each scaffold for 5 minutes and images 
were acquired using a Nikon fluorescence microscope (10 X) by FITC (green) 
and TRITC (red) filters. All images were overlaid with FITC and TRITC channels 
to indicate respectively live and dead cells. 
 
2.13 DAPI/Actin Green assay 
The confocal microscopy analysis was performed to evaluate the colonization 
rate of the MatriDerm® scaffold by H-GMSCs and P-GMSCs (P5) and the 
distribution of the cells.  
Briefly, after 2, 7 and 10 days, the scaffolds were fixed with 4% paraformaldehyde 
in DPBS (300 μl) at room temperature for 15 minutes. They were washed with 
DPBS and incubated with 0,1% Triton-X 100 in DPBS (300 μl) at room 
temperature for 4 minutes. Finally, they were incubated with 1:1000 DAPI (Sigma 
Aldrich, Milan, Italy) in distilled H2O (300 μl) at room temperature for 30 minutes 
to stain the nuclei, and 2 drops/ml ActinGreen™ 488 ReadyProbes™ Reagent 
(Thermo Fisher Scientific, Milan, Italy) in DPBS (300 μl) at room temperature for 
1 hour to stain cellular cytoskeleton. 
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The scaffolds were analyzed by a Nikon A1 confocal microscope and the software 
ImageJ (http://imagej.nih.gov/ij/). The volumetric analysis has been performed by 
NIS Elements AR software (Nikon). 
 
2.14 In vitro GMSC bone differentiation on the MatriDerm® scaffold 
To test the bone differentiation ability of H-GMSCs and P-GMSCs (P3) grown in 
the MatriDerm® scaffold, the cells were grown in 24 well plates to confluence 
under standard culture conditions and then maintained in home-made osteogenic 
differentiation medium (ODM) consisting of: DMEM F-12 supplemented with 10% 
FBS, 10 nM dexamethasone (Sigma Aldrich, Milan, Italy), 10 mM 
glycerophosphate (Sigma Aldrich, Milan, Italy), and 0.05 mM ascorbic acid 
(Sigma Aldrich, Milan, Italy), with or without the isoflavone Biochanin A at two 
different concentrations, 300 nM and 1 μM. H-GMSCs and P-GMSCs cultured 
without scaffolds were used as control. After 21 days of culture in the ODM, H-
GMSCs and P-GMSCs with or without the scaffolds were stained with Alizarin 
Red S (Sigma Aldrich, Milan, Italy) to detect the calcium deposits. Briefly, 
scaffolds were transferred in a new 24 well plate and H-GMSCs and P-GMSCs 
with or without the scaffolds were gently washed with DPBS, fixed with 4% 
paraformaldehyde solution for 15 minutes at room temperature and rinsed twice 
with distilled H2O. Cells were stained with 40 mM Alizarin Red S (pH 4.1) for 30 
minutes at room temperature with gentle shaking, washed with DPBS and 
observed under a light optical microscope. The images were acquired with a 
Nikon DS-fi1. Due to the thickness of the scaffolds, only images of control H-
GMSCs and P-GMSCs were acquired. The quantification of the calcium deposits 
in H-GMSCs and P-GMSCs with or without the scaffolds was then evaluated by 
measurement of Alizarin Red S optical density (OD) at 550 nm. Three sets of 
experiments for each sample were performed for calculations. 
 
2.15 In vivo GMSC bone differentiation on the MatriDerm® scaffold 
All experimental procedures and protocols were approved by the “OPBA – 
Organismo Preposto al Benessere degli Animali” of the “A.Mirri” Experimental  
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Zooprophylactic Institute of Sicily (approval No. 1061/2015) and by the Italian 
Minister of Health (approval No.383/2018). 
All the surgical procedures will be performed at the “A.Mirri” Experimental 
Zooprophylactic Institute of Sicily. 
Twenty-four (24) 4 week-old athimic immunodeficient nude rats will be used for 
the study. All animals will be housed in the facility of the “A.Mirri” Experimental 
Zooprophylactic Institute of Sicily, and maintained on a 12-h light/12-h dark cycle 
with free access to rodent feeding and water. After two weeks of housing in well-
controlled conditions of temperature, light and humidity, the animals will be 
randomly divided into groups for the experiment as follows (see Fig.1):  
1) time-point 1 (4 weeks) including 8 animals; 4 animals receiving MatriDerm® 
scaffold/H-GMSCs, 4 animals receiving MatriDerm® scaffold/P-GMSCs; 
2) time-point 2 (6 weeks) including 8 animals; 4 animals receiving MatriDerm® 
scaffold/H-GMSCs, 4 animals receiving MatriDerm® scaffold/P-GMSCs; 
3) time-point 3 (8 weeks) including 8 animals; 4 animals receiving MatriDerm® 
scaffold/H-GMSCs, 4 animals receiving MatriDerm® scaffold/P-GMSCs. 
In detail, 200.000 cells will be seeded on each scaffold under standard culture 
conditions; after having reached the confluence, they will be maintained in ODM 
for 1 week to induce bone differentiation; for each group, a suspension of H-
GMSCs and P-GMSCs without the scaffold will be prepared as a control. Next, 
the scaffolds with pre-conditioned H-GMSCs/P-GMSCs and the cell suspension 
of pre-conditioned H-GMSCs/P-GMSCs will be respectively implanted and 
injected subcutaneously on the right side and the left side of the dorsal surface 
of each group of animals. 
After each time-point, the animals will be sacrificed and dissected to explant the 
scaffolds and the control tissues afterward used to perform histological analysis 
and RT-qPCR analysis of bone differentiation markers: RUNX2; Osteopontin 
(OPN); Osteocalcin (OCN); Alkaline Phosphatase (ALP) and Collagen 1 A1 
(COL1A1). 
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2.16 Statistical analysis 
All the experiments of the study were performed in triplicate, and results are 
reported as means ± SD and compared by the Student’s unpaired two-sample T-
test. P £ 0.05 was considered statistically significant. 
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CHAPTER 3 
 
 
Results 
 
 
3.1 Proliferation rate of adherent H-GMSCs and P-GMSCs  
22 Healthy patients (Control group) and 26 periodontally-affected patients (Test 
group) were used in the study to isolate DPSCs and GMSCs. For each patient, a 
gingival flap was used to extract gingival tissue. None of the harvested dental 
pulp tissues allowed the isolation of DPSCs, because of low cell yield and/or high 
rate of bacterial contamination. Ten of the harvested gingival tissues, respectively 
4 of the Control group and 6 of the Test group were removed from the study, 
because of high bacterial contamination. For all the 38 gingival samples, after a 
sequential mechanic and enzymatic digestion, it was generated a cell suspension 
as it is shown in the Figure 2 A, B. Primary cells (P0), derived from both Control 
and Test group, started to adhere to the flask approximately between the 4° and 
the 5° day from digestion. All gingival primary cells from both Control and Test 
group cultures showed a typical fibroblast-like morphology, an homogeneous 
shape and size (Fig. 2 C, D) and reached 80% of confluence between 12 and 18 
days; both populations initially showed the same rate of cell growth. After having 
reached the confluence, they were trypsinized and sub-cultured referring to them 
as P1 and showed a modification in behavior: as it is highlighted in cell growth 
curve (Fig. 3 A), 24 h after seeding, P-GMSCs started to proliferate faster than 
H-GMSCs, showing a higher proliferation rate. The doubling time (DT) was 
calculated as 26.4 ± 2 h vs. 30.2 ± 1 h (p£0.05) respectively for P-GMSCs and 
H-GMSCs (Fig. 3 B). 
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3.2  Clonogenic potential of H-GMSCs and P-GMSCs  
To analyze the clonogenic potential of H-GMSCs and P-GMSCs, the CFU assay 
was performed. GMSCs from both Control and Test group were able to form 
adherent colony-forming units on plastic dish after 14 days of incubation under 
standard conditions (Fig. 3 C), even if an increase in the number of CFU colonies 
was observed in P-GMSCs compared to the healthy counterpart, thus showing a 
higher clonogenic activity. The counting performed by software ImageJ showed 
156.8 ± 9.3 and 116.7 ± 5.9 (p£0.01) CFU colonies after 14 days of culture (Fig. 
3 D) respectively for P-GMSCs and H-GMSCs.  
 
3.3  Immunophenotyping of H-GMSCs and P-GMSCs  
Both population of GMSCs analyzed resulted negative for the hematopoietic 
surface markers CD45 and HLA-DR (Fig. 4 A) and positive for putative adult MSC 
surface markers CD73, CD29, CD90 and CD105 (Fig. 4 B). CD73 and CD29 
were highly expressed in all samples (approximately 100 %); however, a slightly 
increased expression of CD90 and CD105 was detected in P-GMSCs compared 
to H-GMSCs (p£0.05) (Table 3). 
The expression of adult MSC nuclear markers Oct4, SOX2 and NANOG was 
positive in both populations, even if it was higher in P-GMSCs than H-GMSCs 
(p£0.05) (Fig. 4 C). The adult MSC profile was more highly expressed in P-
GMSCs than H-GMSCs. 
 
3.4  WST1 cell viability assay on the FISIOGRAFT Bone Granular® 
H-GMSCs and P-GMSCs were seeded on the FISIOGRAFT Bone Granular® in 
presence of low-adhesion conditions and the viability evaluated at 24, 48 and 72 
hours by WST1 assay (Fig. 5 A). The histogram showed that the viability of H-
GMSCs and P-GMSCs, grown in presence of the scaffold, results decreased 
(approximately 50 %) compared to H-GMSCs and P-GMSCs, grown without the 
scaffold, both in standard and low-adhesion conditions, demonstrating that the 
properties of the scaffold are not suitable for in vitro experimental purposes. 
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3.5  MTT cell viability assay on the MatriDerm® scaffold 
H-GMSCs and P-GMSCs were seeded on the MatriDerm® scaffold for 24, 48 
and 72 hours and the viability was then evaluated by MTT assay (Fig. 5 B). The 
data displayed in the histogram demonstrated the continuous cell growth in 
presence of the scaffold and a higher proliferation rate of both H-GMSCs and P-
GMSCs in presence of the scaffold compared to control cells, grown without the 
scaffold. As expected, the proliferation rate of P-GMSCs was higher than H-
GMSCs. 
 
3.6  Live/Dead assay on the MatriDerm® scaffold 
The viability and the distribution of GMSCs from healthy and periodontally-
affected tissues in the MatriDerm® scaffold was also evidenced by the Live/Dead 
assay (Fig. 6 A). Approximately 100% of both H-GMSCs and P-GMSCs, seeded 
in the scaffold for 24, 48 and 72 hours, were viable; the density of the cells 
increased in every time-point and was higher for P-GMSCs than H-GMSCs. We 
also observed that both H-GMSCs and P-GMSCs tended to align along the 
direction of collagen fibrils.  
 
3.7  DAPI/Actin Green assay on the MatriDerm® scaffold 
After nuclear and cytoskeleton staining, a confocal microscopy analysis was 
performed to evaluate the colonization rate of the MatriDerm® scaffold by H-
GMSCs and P-GMSCs after 2, 7 and 10 days of culture under standard 
conditions. Different areas of the scaffold were taken into consideration and 
images were acquired. Considering the thickness of the scaffold used (1 mm), 
the results in Fig. 6 B showed that both H-GMSCs and P-GMSCs were able to 
colonize roughly 200 µm of the scaffold and were homogeneously distributed in 
the axis x and y. In particular, H-GMSCs colonized 190,336 µm of the scaffold in 
depth, P-GMSCs colonized 182,80 µm of the scaffold in depth.  In addition, we 
observed an increased density of cells up to 10 days, with a higher increase for 
P-GMSCs compared to H-GMSCs, demonstrating the ability of the cells to 
colonize the scaffold and grow homogeneously. 
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3.8  In vitro H-GMSC and P-GMSC bone differentiation on the MatriDerm® 
scaffold 
To test the bone differentiation ability of H-GMSCs and P-GMSCs seeded on the 
MatriDerm® scaffold, the cells, with or without the scaffold, were grown to 
confluence in 24 well plates under standard culture conditions and then 
maintained in home-made ODM, in presence or not of 300 nM and 1 μM 
Biochanin A; the bone differentiation rate was assessed by Red S Alizarin assay 
(Fig.7). After 21 days, the MatriDerm® scaffold seems to support the bone 
differentiation of H-GMSCs and P-GMSCs with an increase in osteoblastic 
differentiation ability of GMSCs grown in the scaffold (p£0.05); moreover, the 
presence of Biochanin A at the concentration of 1 μM seems to induce a slight 
increase in bone differentiation with respect to the standard ODM (Fig. 7 A, B). 
 
3.9  In vivo H-GMSC and P-GMSC bone differentiation on the MatriDerm® 
scaffold 
After evaluation of experimental in vitro results, it is planned to use twenty-four 
(24) 4 week-old athymic immunodeficient nude rats for the in vivo study.  
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CHAPTER 4 
 
 
 
Discussion 
 
 
Periodontitis is prevalent both in developed and developing countries and affects 
roughly the 20-50% of the global population. The high prevalence of periodontitis 
in young and old people makes it a serious public health concern. It occurs when 
the inflammation on gingival tissue, mainly induced by the microorganisms of the 
dental plaque, is not properly treated and the gingiva, along with periodontal 
ligament and alveolar bone, progressively resorbs creating a pocket responsible 
for tooth loss 7,8. In these patients, no dental implant can be placed and the 
physiological oral functions are seriously compromised 11,12,91. 
 
Integrated in the PON R&I 2014-2020, this PhD thesis is in line with the SNSI that 
promotes the smart and inclusive development of the country. With a particular 
interest on the Health Specialization Area, this PhD project aims to improve the 
life quality of patients with chronic-degenerative diseases as periodontitis. 
 
Nowadays, GBR represents the most used protocol to regenerate the bone and 
allow the placement of dental implants 19. In particular thanks to the high 
biocompatibility, osteoinductive and osteoconductive properties, the autologous 
bone graft represents the “gold standard” of GBR; however, it requires a second 
surgical site, which means higher costs of interventions and increased probability 
of clinical complications 19–21; thus, alternative treatments are urgently needed. 
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In the past few years, TERM is one of the most discussed topics in medicine as 
alternative strategy to treat tissue defects; thanks to the well-known properties of 
hMSCs, adult multipotent cells characterized by clonogenicity, self-renewal and 
multi-lineage differentiation, many smart procedures have been developed to 
regenerate tissues as bone 39. In the light of the currently used source of hMSCs 
(i.e. bone marrow, umbilical cord blood and adipose tissue) 35,36, a more 
accessible and low-cost hMSC source is necessary and the oral cavity seems to 
be a valuable candidate 37,41,47–52. Among the different sources of hMSCs 
identified in the mouth 41,47–51, dental pulp and gingiva demonstrated to be very 
promising; DPSCs and GMSCs have high regenerative potential, with even 
increased proliferation and multi-lineage differentiation abilities compared to BM-
MSCs 54,56,61. In addition, it was recently demonstrated that inflammation 
conditions positively influence their stem cell and multi-lineage differentiation 
abilities 44.  
 
Therefore, based on the current national priorities of the technological 
development in the Health Specialization Area (i.e. Regenerative and 
Personalized Medicine),  harvesting hMSCs from oral tissues undergone 
inflammation, as dental pulp and gingiva from periodontally-compromised teeth 
up to now considered waste tissues, constitutes an encouraging, easy and low-
cost alternative to the GBR traditional strategies. 
 
In vitro study 
 
Isolation and promising hMSC properties of P-GMSCs- GMSCs were 
successfully isolated from gingiva of healthy and periodontally-compromised 
teeth, and as previously demonstrated 44, they confirmed to have increased 
clonogenic activity, expression of hMSC markers and increased ability to 
differentiate towards osteoblastic cells than H-GMSCs, confirming that the 
inflamed microenvironment positively affects the regeneration potential of 
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GMSCs. The waste tissue, as gingiva from periodontally-compromised teeth, can 
be successfully employed as a source of autologous hMSCs. 
 
In vitro bone differentiation of P-GMSCs in the Matriderm® scaffold - to 
evaluate if GMSCs from waste gingiva could be successfully employed to 
regenerate the bone, and contribute to the development of a biomedical 
experimental product with a TRL-4, we tested the ability of P-GMSCs and H-
GMSCs to in vitro grow and bone differentiate in two different types of scaffolds 
provided by the companies involved in the study: FISIOGRAFT Bone Granular® 
and Matriderm®.  
HA and calcium phosphate derivates, that mimic the inorganic phase of the 
natural bone, are widely used for bone regenerative purposes 67,68. The synthetic 
FISIOGRAFT Bone Granular®, provided by the partner company Ghimas Spa, 
consists of HA granules with pores from 500 to 1000 μm and interconnected 
porosity optimal for cell proliferation. The morphological structure of 
FISIOGRAFT Bone Granular® mimics the trabecular bone, allowing the new 
bone to greatly occupy the volume of the scaffold. The FISIOGRAFT could be a 
promising scaffold to support the growth and the bone differentiation of GMSCs. 
A recent clinical study on patients with maxillary sinus bone defect showed that 
it successfully regenerates the bone defect 71. However, as widely accepted, one 
of the main challenges in the in vitro systems is re-producing the in vivo cell 
microenvironment, which is a very complex task. This is constituted by factors 
able to influence the environment of a cell or a group of cells, with direct or indirect 
effects on cell behavior and phenotype. A single cell is affected by the 
composition and structure of the extracellular matrix surrounding cells, growth 
factors, cytokines, hormones and other bioactive molecules with autocrine, 
endocrine and paracrine effects; besides, physical and mechanical factors, due 
to the movement of the organism or the physiological fluids as blood, have to be 
taken in consideration 92. From our results, deriving from the WST1 viability 
assay, the FISIOGRAFT Bone Granular® doesn’t support the growth of the 
GMSCs in vitro, since approximately 50 % of both P-GMSCs and H-GMSCs 
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showed lower viability in presence of the scaffold. It might be caused by the 
marked difference between the in vitro and the in vivo cellular microenvironment; 
thanks to the in vivo blood supply, many factors can coordinate the biomaterial 
remodeling and degradation along with the attraction of hMSCs to the target site, 
supporting the tissue regeneration. It was demonstrated that the cells have 
different behaviors in 2D and 3D cultures;  they start to behave differently when 
explanted from native three-dimensional (3D) tissues and grow as an in vitro 
monolayer 93. Therefore, depending on the in vitro or the in vivo 
microenvironment, GMSCs could differently react to the presence of the scaffold. 
Type I collagen is the most represented organic polymer of bone matrix and plays 
an important role in the process of bone formation and remodeling. For these 
reasons, nowadays, also thanks to the excellent biocompatibility, biodegradability 
and weak antigenicity, and the ability of the fibrils to guide the bone 
mineralization, the collagen is widely used for tissue regeneration 72,73. We tested 
the in vitro growth and bone differentiation properties of P-GMSCs and H-GMSCs 
on the MatriDerm® scaffold, a three-dimensional matrix consisting of collagen 
type I (bovine collagen) and elastin with a porosity approximately of 100 µm, from 
the company Medskin Solution (Dr. Otto Suwelack Skin and Health Care GmbH, 
Billerbeck, Germany). Our study demonstrated that MatriDerm® can support the 
growth of H-GMSCs and P-GMSCs. The viability results showed a progressively 
increasing rate of cell growth in presence of the scaffold. These data were also 
confirmed by the Live/Dead and DAPI/Actin Green assays, demonstrating that 
the H-GMSCs and P-GMSCs, showing the typical fibroblast-like shape, 
homogeneously colonized the scaffold guided by the collagen fibrils. In addition, 
we observed an increased cell density up to 10 days of culture. These data 
suggested that the MatriDerm® scaffold may promote the adhesion and growth 
of GMSCs both from Control and Test group. 
To assess the bone differentiation ability of H-GMSCs and P-GMSCs in the 
MatriDerm® scaffold, they were grown on the scaffold under osteoblastic 
differentiation conditions. The results derived from Alizarin S Red assay showed 
an increased mineralization rate of both H-GMSCs and P-GMSCs grown on the 
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scaffold compared to the control cells. However, it was demonstrated that pure 
collagen materials don’t have enough osteoinductive activity to stimulate bone 
formation, and many strategies, based on scaffold incorporation or MSC 
treatment with bioactive molecules, have been developed 79. Biochanin A (5,7-
dihydroxy-4’-methoxy-isoflavone), an isoflavone most commonly found in 
legumes as red clover (Trifolium pratense), acts as a natural modulator of the α 
and β estrogen receptors 82–86, enhancing the osteoblastic differentiation and 
inhibiting the osteoclastic differentiation 87,88, thus contributing to maintain the 
bone health 80,81. Su et al. recently demonstrated that Biochanin A, with the 
concentration of 300 nM, supports the osteoblastic differentiation 88. A slight 
increase in the mineralization rate of H-GMSCs and P-GMSCs, grown in 
presence of Biochanin A, was observed; however, these results need to be 
confirmed and more deeply investigated in further studies to identify the optimal 
concentration of Biochanin A supporting the bone differentiation, and to evaluate 
the molecular mechanism potentially involved. 
 
In vivo study 
 
The results of the in vitro study lead to evaluate the H-GMSCs and P-GMSC in 
vivo bone regeneration potential in the MatriDerm® scaffold.  
The in vitro results and the successful in vivo application of the MatriDerm® for 
dermal and cartilage regeneration75,76,94, lead us to conceive that the H-GMSCs 
and P-GMSCs, supported by a biocompatible scaffold as MatriDerm®, may 
regenerate the bone in vivo. 
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Conclusions 
Patients suffering from jaw bone loss, as periodontal patients, urgently need a 
low-cost strategy for alveolar bone defect regeneration to place dental implants 
and restore the oral functions. Bone TE along with RM reproduces tissues and 
organs by use of adult hMSCs, smart biomaterials and bioactive molecules.  
The low cell yield and/or high rate of bacterial contamination of the dental pulp 
samples did not allow the isolation and evaluation of bone regeneration potential 
of DPSCs; instead, GMSCs were successfully isolated from healthy and inflamed 
gingiva of periodontally-compromised teeth. Compared to dental pulp, gingiva is 
a more accessible source of hMSCs, and the procedure to isolate the GMSCs is 
quicker and much easier than that one used for DPSCs, resulting a more 
convenient source of autologous hMSCs for clinical routine in line with the 
principles of the SNSI.  
Probably due to the marked difference between the in vitro and the in vivo cellular 
microenvironment and behavior, the H-GMSCs and P-GMSCs were not able to 
grow in the FISIOGRAFT Bone Granular®, but they showed to progressively 
grow, homogeneously distribute and bone differentiate in the MatriDerm® 
scaffold, with a slight increase in the osteodifferentiation rate after treatment with 
the Biochanin A. The results, derived from the integration of the hMSC know-how 
of the University of Palermo and the biomaterial expertise of the partner 
companies, contributed developing a biomedical experimental product that may 
successfully improve the quality of life of the periodontal patients and was 
validated in the laboratory (TRL-4).  
These data need to be further investigated in future studies; however, the results 
suggest that the P-GMSCs from discarded tissues, supported by a biocompatible 
scaffold as MatriDerm®, may really support the development of a low-cost and 
painless strategy of autologous bone tissue regeneration suitable for clinical 
routine; in line with the goals of the PON R&I 2014-2020 and SNSI, this 
represents an easier and 100 % biocompatible alternative to the traditional GBR 
procedures to treat not only bone defects caused by periodontitis but also any 
other type of bone defect. 
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CHAPTER 5 
 
 
Figures and Tables 
 
 
5.2 Tables 
 
 
Table 1: Human anti-monoclonal antibodies list used in flow cytometry analysis 
for mesenchymal stem cell marker detection. 
 
 
 
 
 
 
 
Fluorescently-conjugated 
antibody/localization marker 
Brand/code 
number Dilution Incubation 
CD-105/FITC, surface Milteny Biotec, 130-098-774 1:11 30’, +4°C 
CD-29/FITC, surface Milteny Biotec, 130-101-256 1:11 30’, +4°C 
CD-90/FITC, surface Milteny Biotec, 130-114-859 1:50 30’, +4°C 
CD-73/PE, surface PE Milteny Biotec, 130-111-908 1:50 30’, +4°C 
CD-45/FITC, surface Milteny Biotec, 130-110-631 1:50 30’, +4°C 
HLA-DR/FITC, surface BD Pharmingen, 555811 1:5 30’, +4°C 
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Table 2: Real-Time qPCR primer sequence list for amplification of mesenchymal 
stem cell cDNA. 
 
F=forward; R=reverse 
 
 
 
 
 
 
Gene Primer sequence 
Brand/code 
number 
b-actin 
F:5'CCACACTGTGCCCATCTACG3' 
R:5'AGGATCTTCATGAGGTAGTCAGTCAG3' 
Eurofins Genomics 
Nanog  QT01844808 
Oct3/4  QT00210840 
SOX2 
F:5'GGAGACGGAGCTGAAGCCGC3' 
R:5'GACGCGGTCCGGGCTTGTTTT3' 
MWG 
RUNX2 
F:5'TACGACTGGACGCTGGTGC3' 
R:5'TTCATGGGTCGCTTGACGT3' MWG 
OPN 
(Osteopontin) 
F:5'TGTGGGTTTCAGCACTCTGGTCA3' 
R:5'AAGCGAGTTGAATGGTGC3' 
MWG 
OCN 
(Osteocalcin) 
F:5'CTGACCTCACAGATGCCAAG3' 
R:5'GTAGCGCCGGAGTCTGTTC3' MWG 
ALP 
(Alkaline 
Phosphatase) 
F:5’GCTTCAAACCGAGATACAAGCA3’ 
R:5’GCTCGAAGAGACCCAATAGGTAGT3’ 
Eurofins Genomics 
COL1A1 
(Collagen 1 A1) 
F:5’TCTGCGACAACGGCAAGGTG3’ 
R:5’GACGCCGGTGGTTTCTTGGT3’ 
Eurofins Genomics 
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Table 3: Expression levels of MSC markers in healthy and periodontally-affected 
GMSCs. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MSCs CD-105 CD-29 CD-90 CD-73 
H-GMSCs 34.3 ±1.2 98±0.94 82.01±0.81 99.1±0.14 
P-GMSCs 57±2.1 100±0.05 97.05±0.8 99.2±0.5 
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5.3 Figures 
 
 
 
Fig.1 Overview of the experimental protocol for the evaluation of the in vivo bone 
differentiation ability of H-GMSCs and P-GMSCs on MatriDerm® scaffold. In vivo 
imaging, and histological and RT-qPCR analyses of osteoblastic differentiation 
markers analysis are performed at 4, 6 and 8 weeks from day of implantation. 
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Fig.2 GMSC cultures (P0). Representative image of (A) healthy and (B) 
periodontally-compromised GMSCs immediately after mechanical and enzymatic 
digestion, showing a rounded morphology (10X); representative image of (C) 
healthy and (D) periodontally-compromised GMSCs at 7° day from digestion, with 
the typical fibroblast-like morphology (10X). 
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Fig. 3  Cell growth analysis and Colony-Forming Unit Fibroblast Assay (CFU-F). 
Figures (A) and (B) respectively show the cell growth curve of H-GMSCs and P-
GMSCs (P2) evaluated by Trypan blue viability assay and the doubling time of 
H-GMSCs and P-GMSCs calculated according to the literature data 
(http://www.doublingtime. com/compute.php); figures (C) and (D) respectively 
show the colonies (<50 cells) (left) and the monolayer subculture (right) of H-
GMSCs and P-GMSCs (P1) stained with Crystal Violet, and the quantification 
histogram of the CFU-F; data are reported as mean values ± SD of three 
independent experiments. P-value *P£0.05; **P£0.01. 
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Fig.4  Mesenchymal stem cell feature analysis. Representative fields of flow-
cytometric analysis of (A) hematopoietic stem cell markers CD45 and HLA-DR 
and (B) MSC markers CD29, CD73, CD90 and CD105 in H-GMSCs and P-
GMSCs (P5) (control: isotype anti-IgG1 for CD45, CD29, CD90, CD73 and 
CD105; isotype anti-IgG2 for HLA-DR); (C) the histogram shows the expression 
of nuclear MSC markers NANOG; Oct4 and SOX-2 in H-GMSCs and P-GMSCs 
(P3). Data are reported as mean values ± SD of three independent experiments. 
Actin-β was used as housekeeping gene; FC= fold change; the mRNA 
expression of analyzed genes was normalized against BM-MSCs (positive 
control); p-value *P£0.05. 
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Fig.5 Cell viability analysis. (A) WST1 viability values of H-GMSCs and P-GMSCs 
(P3) grown in the FISIOGRAFT Bone Granular® scaffold for 24, 48 and 72 hours; 
(B) MTT viability values of H-GMSCs and P-GMSCs (P3) grown in the 
MatriDerm® collagen scaffold for 24, 48 and 72 hours; data are reported as mean 
values ± SD of three independent experiments; p-values *P£0.05, **P£0.01, 
***P£0.001. 
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Fig. 6 Cell distribution analysis. (A) Fluorescent representative images of a 
Live/Dead assay of H-GMSCs and P-GMSCs (P5) grown for 24, 48 and 72 hours 
in the MatriDerm® collagen scaffold (4X); (B) (left) MaxI P and (right) volumetric 
images of DAPI/Actin Green confocal microscopy assay of H-GMSCs and P-
GMSCs (P5) grown for 2, 7 and 10 days in the MatriDerm® collagen scaffold 
(4X); scale bars = 100 μm; depth=190,336 μm for H-GMSCs; depth=182,80 μm 
for P-GMSCs. 
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Fig. 7 Osteoblastic differentiation assay. (A) Representative images of control H-
GMSCs and P-GMSCs grown in osteogenic differentiation medium (ODM), with 
or without Biochanin A 300 nM and 1 μM, and stained with Red S Alizarin (4X); 
(B) histogram representing the quantitative analysis of Red S Alizarin by 
spectrophotometry (550 nm OD), of H-GMSCs and P-GMSCs grown in ODM, in 
presence or not of the MatriDerm® collagen scaffold, with or without Biochanin A 
300 nM and 1 μM. Data are reported as mean values ± SD of three independent 
experiments; p-values *P£0.05. 
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